Cytodyn Inc Developing New Therapies for Treatment of Human Immunodeficiency Virus Transcript
Hi. I'm Mike Elliott and you're watching The StockGeek Podcast where we help investors find potentially profitable small- and mid-cap stocks that may be undervalued, on the verge of a breakout or have other fundamental characteristics that make them an attractive long-term opportunity.
Today, as part of our CEORoadshow series were joined by Dr. Nader Pourhassan, President and CEO of CytoDyn, a biotech company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. They trade under the ticker CYDY.
Hi, Dr. Pourhassan and welcome to the show.
Thank you for having me.
Questions & Answers
For investors new to the story, I'd like to start off by getting an overview of what CytoDyn does, what are your primary pipeline drugs right
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
